Cytology News and Research

RSS

Cytology is the study of cells using a microscope.

Biomoda's CyPath assay for lung cancer detection receives Canadian patent

Cancer diagnostics company Biomoda, Inc. has received a notice of allowance for a Canadian patent application for a method of using its proprietary porphyrin-based compound that binds to cancer cells and causes them to fluoresce under specific frequencies of light when viewed under a fluorescent microscope.

26 Aug 2010

Norwegian cervical screening program begins reimbursing for liquid-based cytology

Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced that on July 1, 2010, the Norwegian cervical screening program began reimbursing for liquid-based cytology (LBC).

6 Aug 2010

Enzo Clinical Labs appointed as participating laboratory in Empire BlueCross BlueShield provider network

Enzo Biochem Inc.'s wholly-owned subsidiary, Enzo Clinical Labs, Inc., and Empire BlueCross BlueShield, the largest health insurer in New York State, today jointly announced that effective August 1, 2010 Enzo Clinical Labs will be a participating laboratory in the Empire provider network for the metropolitan New York area.

3 Aug 2010

Patent application for inexpensive CyPath assay filed by Biomoda

Cancer diagnostics company Biomoda,filed a U.S. patent application on a quantitative method for scoring cells labeled with the CyPath® assay to determine whether cells are dysplastic or carcinomic by measuring the photon emission rate.

21 Jul 2010

Study compares denture stomatitis genes with whole transcriptome for salivary biomarker analysis

The goal of the study was to compare whole-transcriptome, mucosal gene expression in Candida albicans (a parasitic fungus that can infect the mouth) associated chronic denture stomatitis to that of healthy oral mucosa and perform proteomic analyses of potential salivary biomarkers. Denture stomatitis is a condition in which the mucosa underneath a denture becomes inflamed and sometimes painful.

16 Jul 2010

Cervical cancer vaccine could reduce number of cases from 3,000 to less than 700 every year

The cervical cancer vaccine could prevent even more cases of the disease in England than previously thought, UK scientists have found.

15 Jul 2010

QIAGEN's digene HPV Test improves cervical cancer control: Study

A study released today "online first" in Cancer Causes & Control demonstrates that human papillomavirus testing, using QIAGEN's digene HPV Test, improved cervical cancer control compared to routine Pap (cytology) testing among 50,000 women across Mexico, the first country in Latin America to implement a national screening program for the high-risk types of HPV that can cause cervical cancer.

From QIAGEN Manchester Limited 13 Jul 2010

OPMEDIC GROUP third-quarter revenue up 9% to $3.899 million

OPMEDIC GROUP Inc., a healthcare-related company in fertility, laboratories and surgeries providing services and facilities to patients and surgeons, is pleased to announce financial results for the third quarter ended May 31, 2010.

9 Jul 2010

HPV DNA testing for precancer, cervical cancer is more sensitive than cytology testing: Study

HPV DNA testing for precancers and cervical cancers is over 50 per cent more sensitive than cytology testing for the same conditions a community-based study in Mexico has revealed. Results of the largest HPV DNA primary screening study ever to be performed in a Latin American country point to the readiness of HPV DNA testing for large-scale implementation in Mexico and are published online today (8 July 2010) in Cancer, Causes and Controls.

9 Jul 2010

Screening for HPV genotypes 16 and 18 helps detect cervical pre-cancer missed by Pap test

Roche today announced that data from the ATHENA (Addressing THE Need for Advanced HPV Diagnostics) U.S. registration trial of over 47,000 women demonstrate that two human papillomavirus genotypes, HPV 16 and HPV 18, can identify those women with cervical pre-cancer missed by cytologic examination with a Papanicolau (Pap) test.

From Roche Sequencing and Life Science 9 Jul 2010

Clinical performance data of Cervista HPV HR presented at International Papillomavirus Conference

Hologic, Inc., a leading women's healthcare company, today announced that final data analysis from the first large-scale independent evaluation of clinical performance of Cervista HPV HR compared to Hybrid Capture 2, were presented in Montreal, Canada, at the 26th International Papillomavirus Conference. Cervista HPV HR is a diagnostic test for the detection of 14 high-risk human papillomavirus types.

8 Jul 2010

QIAGEN receives CE conformity marking for careHPV Test

QIAGEN has completed European certification of its careHPV™ Test to bring human papillomavirus (HPV) testing to public-health programs in low-resource, developing countries, the company announced today at the International Papillomavirus Conference in Montreal, Canada. The CE conformity marking ("Conformite Europeenne") certifies that the careHPV Test has met European Union consumer safety and health requirements, allowing the test to be distributed in developing countries that recognize the CE mark.

From QIAGEN Manchester Limited 7 Jul 2010

Zetiq completes clinical trial of CellDetect technology for early identification of cervical cancer

Zetiq Technologies Ltd., a subsidiary of Bio-Light Ltd., reports the successful completion of another clinical trial to validate the effectiveness of the company's technology for early identification and diagnosis of cervical cancer, in conventional cytological smears.

24 Jun 2010

Study demonstrates p53 protein becomes activated during gamete formation

Protein p53 is known as the guardian of the genome since it is basic for the genome's integrity by preventing the accumulation of mutations originating either by the cell's own mechanisms or by the action of external agents.

11 Jun 2010

Veracyte announces completion of Series B round

Veracyte, Inc. announced today the successful completion of its Series B round, a key milestone toward the company's first product launch later this year. The South San Francisco biotechnology company is committed to pioneering molecular cytology diagnostics to improve patient care and lower health care costs. This round was led by Domain Associates with significant participation from Veracyte's founding investors including Kleiner Perkins Caufield & Byers (KPCB), TPG Biotech (TPG), and Versant Ventures.

10 Jun 2010

Protein p53 becomes activated to control creation of ova and spermatozoids: Study

Protein 53 is very important in protecting against cancer given that it prevents cancer-causing mutations from accumulating and its inactivation is closely linked to the proliferation of tumour cells. UAB lecturer Ignasi Roig participated in the study. Formed by an international research team, the study served to discover that this protein played an unexpected physiological role: it also becomes activated during the formation process of ova and spermatozoids.

8 Jun 2010

Biomoda granted Mexican patent for proprietary porphyrin-based compound

Cancer diagnostics company Biomoda, Inc. has been granted a Mexican patent for its proprietary porphyrin-based compound that binds to cancer cells and causes them to fluoresce red under ultraviolet light.

7 Jun 2010

Promising results of ABRAXANE for bladder cancer support efficacy of nab-driven chemotherapy

Abraxis BioScience, Inc. announced today that findings from a phase 1 randomized trial demonstrated that the nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension) is well-tolerated and active in the second-line treatment of high-grade, non-muscle-invasive bladder cancer that has been refractory to standard intra-bladder infusion (intravesical) therapy.

4 Jun 2010

FDA approves Cysview for detection of non-muscle-invasive papillary cancer of bladder

GE Healthcare, a unit of General Electric Company, today announced that the US Food and Drug Administration has approved Cysview (hexaminolevulinate HCl) for the detection of non-muscle-invasive papillary cancer of the bladder in patients with known or suspected bladder cancer.

29 May 2010

HPV test recommended for national cervical cancer screening programmes

Two studies suggest that testing for the human papillomavirus (HPV) - the major cause of cervical cancer - could be used in national cervical cancer screening programmes.

4 May 2010